DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, is offering a new program designed to provide support for individuals using GLP-1s and other anti-obesity drugs. The program is designed to support changes in behavior and help users leverage the full potential of medications while improving overall health; the program also has potential to deliver valuable insights to Dario’s partners. GLP-1s weight-loss medications are approved for use by adults with certain related chronic conditions. Dario’s new whole-health program is designed to help people reach their weight-loss goals. The company’s proven combination of innovative technologies and human support focuses on changing underlying health behaviors. According to the announcement, members using a GLP-1 or other anti-obesity medications who enroll in Dario’s cardiometabolic solution will receive a highly personalized experience optimizing digital coaching and professional human support to improve overall health. In addition, members will be able to access DRIO’s new Medication Cabinet, which is a digital tool designed to assist members in tracking medication adherence. “The standard of care for obesity is evolving, and we believe Dario’s proven ability to sustainably change behaviors will best help our members and partners realize the full potential of these anti-obesity medications: long-term weight loss and better overall health,” said Dario president Rick Anderson in the press release. “Our wealth of data insights today guides member engagement alongside medical weight loss interventions, and this new program adds a new dimension to the level of insights and guidance we can provide our partners on this emerging priority.”
To view the full press release, visit https://ibn.fm/1rA4h
About DarioHealth Corp.
DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
